Market Overview:
The global preimplantation genetic diagnosis (PGD) market is expected to reach USD 1,711.8 million by 2030 from USD 706.5 million in 2018, at a CAGR of 16.1%. The growth of the PGD market is mainly driven by the increasing demand for PGD services due to rising incidence of genetic disorders, technological advancements in PGD procedures, and growing awareness about PGD among couples planning pregnancy. However, the high cost of PGD procedures may restrain the growth of this market to some extent during the forecast period. On the basis of type, the global preimplantation genetic diagnosis (PGD) market is segmented into genetic diagnosis and genetic screening. The Genetic Diagnosis segment accounted for major share of this market in 2017 and is projected to grow at a higher CAGR during forecast period owing to increasing use of this technology for detection & identification offertile couples carrying chromosomal abnormalities or specific single gene defects . On basis on application ,the global preimplantation Genetic Diagnosis(PG D)marketis segmentedinto fertility clinicsand research institutions .
Product Definition:
Preimplantation Genetic Diagnosis is a process that can be used to detect genetic abnormalities in embryos before they are implanted into the uterus. This is important because it can help couples who are at risk for passing on genetic disorders to their children choose embryos that do not have the disorder.
Genetic Diagnosis:
Genetic diagnosis is the process of determining whether a person has inherited a harmful gene from an affected parent, which can cause disease in the future. Genetic testing or prenatal screening is used to diagnose genetic diseases in fetus during pregnancy. This service allows detection of genetic abnormalities in fetus and provides information about possible risks and their management options before birth.
Genetic Screening:
Genetic screening is the process of testing a person's genes to see if they are susceptible to certain diseases or conditions. This can be used for hereditary diseases, common genetic disorders, and cancer susceptibility. In prenatal testing this procedure is used for detecting Down syndrome (trisomy 21), Edward syndrome (trisomy 18), Patau syndrome (patau disease), and other genetic abnormalities in the fetus.
Application Insights:
Based on application, the global market is segmented into fertility clinics, research and other institutions. The fertility clinics segment dominated the overall market in terms of revenue share in 2017. This can be attributed to a rise in demand for assisted reproductive technology procedures such as In-vitro Fertilization (IVF) and Assisted Hatching Technology (AHT). Moreover, an increase in number of IVF cycles performed has also fueled growth over the years.
The research institutes segment is expected to witness lucrative CAGR during the forecast period owing to increasing R&D activities pertaining toPGD applications at a domestic level as well as across various countries globally.
Regional Analysis:
Europe dominated the global preimplantation genetic diagnosis market in 2017. This can be attributed to factors such as favorable reimbursement policies, presence of well-established healthcare facilities and availability of advanced technologies forPGD. In addition, increasing infertility rate and rising awareness about IVF procedures are some other factors responsible for Europe’s dominance in the market.
Asia Pacific region is expected to grow at a lucrative CAGR over the forecast period owing its developing economy along with supportive government initiatives & programs aimed at improving access towards high-quality healthcare services & products especially related fertility treatment methods such as PGTDs that offer definitive answers regarding disease status thus reducing uncertainty associated with it thereby boosting adoption rates among patients across this region.
Growth Factors:
- Increasing demand for PGD services owing to rising incidence of genetic disorders and chromosomal abnormalities.
- Growing awareness about the benefits of PGD among couples planning to conceive a child.
- Proliferation of advanced technologies in preimplantation genetic diagnosis that facilitate accurate diagnosis of genetic disorders and abnormalities.
- Rising number of fertility clinics offering PGD services worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Preimplantation Genetic Diagnosis Market Research Report
By Type
Genetic Diagnosis, Genetic Screening
By Application
Fertility Clinics, Research
By Companies
Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Coopersurgical, ABBott Laboratories, Natera, Inc., Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Preimplantation Genetic Diagnosis Market Report Segments:
The global Preimplantation Genetic Diagnosis market is segmented on the basis of:
Types
Genetic Diagnosis, Genetic Screening
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Fertility Clinics, Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Perkinelmer, Inc.
- Coopersurgical
- ABBott Laboratories
- Natera, Inc.
- Rubicon Genomics
- Oxford Gene Technology
- Yikon Genomics
- Scigene
Highlights of The Preimplantation Genetic Diagnosis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Genetic Diagnosis
- Genetic Screening
- By Application:
- Fertility Clinics
- Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Preimplantation Genetic Diagnosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Preimplantation genetic diagnosis (PGD) is a procedure used to diagnose genetic disorders in embryos before they are implanted into the uterus. PGD is performed by taking a sample of an embryou2019s cells and testing them for mutations that can be associated with certain diseases. If a mutation is found, the embryo can be discarded or used in another fertility treatment.
Some of the key players operating in the preimplantation genetic diagnosis market are Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Coopersurgical, ABBott Laboratories, Natera, Inc., Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene.
The preimplantation genetic diagnosis market is expected to grow at a compound annual growth rate of 16.1%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Preimplantation Genetic Diagnosis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Preimplantation Genetic Diagnosis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Preimplantation Genetic Diagnosis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Preimplantation Genetic Diagnosis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Preimplantation Genetic Diagnosis Market Size & Forecast, 2018-2028
4.5.1 Preimplantation Genetic Diagnosis Market Size and Y-o-Y Growth
4.5.2 Preimplantation Genetic Diagnosis Market Absolute $ Opportunity
Chapter 5 Global Preimplantation Genetic Diagnosis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Preimplantation Genetic Diagnosis Market Size Forecast by Type
5.2.1 Genetic Diagnosis
5.2.2 Genetic Screening
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Preimplantation Genetic Diagnosis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Preimplantation Genetic Diagnosis Market Size Forecast by Applications
6.2.1 Fertility Clinics
6.2.2 Research
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Preimplantation Genetic Diagnosis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Preimplantation Genetic Diagnosis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Preimplantation Genetic Diagnosis Analysis and Forecast
9.1 Introduction
9.2 North America Preimplantation Genetic Diagnosis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Preimplantation Genetic Diagnosis Market Size Forecast by Type
9.6.1 Genetic Diagnosis
9.6.2 Genetic Screening
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Preimplantation Genetic Diagnosis Market Size Forecast by Applications
9.10.1 Fertility Clinics
9.10.2 Research
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Preimplantation Genetic Diagnosis Analysis and Forecast
10.1 Introduction
10.2 Europe Preimplantation Genetic Diagnosis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Preimplantation Genetic Diagnosis Market Size Forecast by Type
10.6.1 Genetic Diagnosis
10.6.2 Genetic Screening
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Preimplantation Genetic Diagnosis Market Size Forecast by Applications
10.10.1 Fertility Clinics
10.10.2 Research
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Preimplantation Genetic Diagnosis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Preimplantation Genetic Diagnosis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Preimplantation Genetic Diagnosis Market Size Forecast by Type
11.6.1 Genetic Diagnosis
11.6.2 Genetic Screening
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Preimplantation Genetic Diagnosis Market Size Forecast by Applications
11.10.1 Fertility Clinics
11.10.2 Research
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Preimplantation Genetic Diagnosis Analysis and Forecast
12.1 Introduction
12.2 Latin America Preimplantation Genetic Diagnosis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Preimplantation Genetic Diagnosis Market Size Forecast by Type
12.6.1 Genetic Diagnosis
12.6.2 Genetic Screening
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Preimplantation Genetic Diagnosis Market Size Forecast by Applications
12.10.1 Fertility Clinics
12.10.2 Research
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Preimplantation Genetic Diagnosis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Preimplantation Genetic Diagnosis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Preimplantation Genetic Diagnosis Market Size Forecast by Type
13.6.1 Genetic Diagnosis
13.6.2 Genetic Screening
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Preimplantation Genetic Diagnosis Market Size Forecast by Applications
13.10.1 Fertility Clinics
13.10.2 Research
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Preimplantation Genetic Diagnosis Market: Competitive Dashboard
14.2 Global Preimplantation Genetic Diagnosis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Illumina, Inc.
14.3.2 Thermo Fisher Scientific Inc.
14.3.3 Agilent Technologies, Inc.
14.3.4 Perkinelmer, Inc.
14.3.5 Coopersurgical
14.3.6 ABBott Laboratories
14.3.7 Natera, Inc.
14.3.8 Rubicon Genomics
14.3.9 Oxford Gene Technology
14.3.10 Yikon Genomics
14.3.11 Scigene
